Literature DB >> 16113585

Biology of vascular calcification in renal disease.

Afshin Farzaneh-Far1, Catherine M Shanahan.   

Abstract

The high rates of atherosclerotic vascular disease in patients with end-stage renal disease (ESRD) cannot be fully explained by the excess of traditional risk factors. Interest has therefore arisen in the possible role of vascular calcification, which is increased in these patients and may effect plaque stability and have detrimental hemodynamic consequences. Considerable evidence has accumulated recently pointing to the regulated nature of the calcification process. The initiation of calcium crystal formation appears to require the presence of small membrane bound vesicles released by living or apoptotic cells. The cellular release, content and phagocytosis of these vesicles appear to be important regulatory pathways in vascular calcification. Better understanding of these mechanisms may have therapeutic potential in reducing the adverse cardiovascular event rates in patients with (ESRD). Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113585     DOI: 10.1159/000087578

Source DB:  PubMed          Journal:  Nephron Exp Nephrol        ISSN: 1660-2129


  3 in total

Review 1.  Direct effects of phosphate on vascular cell function.

Authors:  Wei Ling Lau; Ashwini Pai; Sharon M Moe; Cecilia M Giachelli
Journal:  Adv Chronic Kidney Dis       Date:  2011-03       Impact factor: 3.620

2.  Circulating calcification inhibitors and vascular properties in children after renal transplantation.

Authors:  Marieke J H van Summeren; Jeroen M Hameleers; Leon J Schurgers; Arnold P G Hoeks; Cuno S P M Uiterwaal; Thilo Krüger; Cees Vermeer; Wietse Kuis; Marc R Lilien
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

3.  Zoledronate inhibits phosphate and bone morphogenetic protein 2-induced extracellular calcification of vascular smooth muscle cells in vitro.

Authors:  M L Hu; Y Huang; Z H Zheng; Y Lei; R J Liu; X H Wang; B Lindholm; X Q Yu
Journal:  Exp Ther Med       Date:  2012-03-01       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.